Brief: Medicure Updates On Percutaneous Coronary Intervention Study
04/11/2021 22:15
Nov 4 (Reuters) - Medicure Inc MPH.V :
* MEDICURE ANNOUNCES THAT THE SHORTENED AGGRASTAT® VERSUS
INTEGRILIN® IN PERCUTANEOUS CORONARY INTERVENTION (SAVI-PCI)
STUDY HAS MET ITS PRIMARY ENDPOINT
Source text for Eikon: ID:nCNW6qSwXa
Further company coverage: MPH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicure
See all newsBrief: Medicure Announces Resignation Of Board Member And Grant Of Stock Options
Brief: Medicure Posts Qtrly Earnings Per Share $0.11
Brief: Medicure Reports Financial Results For Quarter Ended June 30, 2022
Brief: Medicure Announces Resignation Of CFO And Succession Plan
Brief: Algernon Pharmaceuticals Appoints James Kinley As CFO Effective From December 1, 2021